for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Akorn, Inc.

AKRX.OQ

Latest Trade

3.74USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

2.35

 - 

5.46

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
3.74
Open
--
Volume
--
3M AVG Volume
32.67
Today's High
--
Today's Low
--
52 Week High
5.46
52 Week Low
2.35
Shares Out (MIL)
126.15
Market Cap (MIL)
470.52
Forward P/E
-31.85
Dividend (Yield %)
--

Latest Developments

More

Akorn Provides Preliminary Third Quarter 2019 Results

Akorn Receives FDA Approval For Betamethasone Dipropionate Lotion USP

Akorn Receives FDA Approval For Azelastine Hydrochloride Nasal Spray

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Akorn, Inc.

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health. The Prescription Pharmaceuticals segment consists of generic and branded prescription pharmaceuticals in a range of dosage forms, including sterile ophthalmics, injectables and inhalants and non-sterile oral liquids, topicals and nasal sprays and otics. The Consumer Health segment consists of branded and private-label OTC products and animal health products dispensed by veterinary professionals. Its branded and private-label OTC products are focused on ophthalmics, including a dry eye treatment TheraTears Therapy for Your Eyes.

Industry

Biotechnology & Drugs

Contact Info

1925 W Field Ct Ste 300

+1.847.2796100

http://www.akorn.com/

Executive Leadership

Alan D. Weinstein

Independent Chairman of the Board

Douglas S. Boothe

President, Chief Executive Officer, Director

Duane A. Portwood

Chief Financial Officer, Executive Vice President

Joseph P. Bonaccorsi

Executive Vice President, General Counsel, Secretary

Dandy Dorado-Boladeres

Executive Vice President of Global Quality

Key Stats

2.75 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

1.1K

2017

0.8K

2018

0.7K

2019(E)

0.7K
EPS (USD)

2016

2.250

2017

1.180

2018

-0.190

2019(E)

-0.117
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.70
Price To Book (MRQ)
1.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
268.42
LT Debt To Equity (MRQ)
0.01
Return on Investment (TTM)
-38.23
Return on Equity (TTM)
-23.39

Latest News

Latest News

Things are getting nasty in the 7th Circuit’s big M&A shareholder class action case

For securities litigators and deal lawyers, the consequences of two related appeals at the 7th U.S. Circuit Court of Appeals, both stemming from shareholder litigation over Akorn’s since-aborted merger with Fresenius Kabi AG, could be huge. The appeals court could provide...

Why would allegedly defrauded Akorn investors want … more Akorn stock?

The generic drugmaker Akorn is facing a world of trouble. The German healthcare giant Fresenius, which received court approval last year to walk away from a $4.75 billion deal to acquire Akorn, is suing Akorn in Delaware Chancery Court for damages from the busted deal. The...

Akorn gets FDA warning letter for another manufacturing plant

Akorn Inc said on Tuesday it received a warning letter from the U.S. Food and Drug Administration regarding its manufacturing facility in New Jersey, the latest in a string of setbacks for the generic drugmaker.

Akorn gets FDA's warning letter related to New Jersey manufacturing plant

Akorn Inc said on Tuesday the U.S. Food and Drug Administration has raised certain issues related to the inspection of its Somerset, New Jersey manufacturing facility in July and August of 2018.

FDA flags concerns at Akorn's Amityville plant, shares slip

Generic drugmaker Akorn Inc said on Thursday the U.S. Food and Drug Administration had raised concerns about its manufacturing plant in Amityville, New York, that included a lack of records on the maintenance and cleaning of equipment.

FDA flags sanitation concerns at Akorn's Amityville plant

Akorn Inc said on Thursday the U.S. Food and Drug Administration issued observations related to inspection of the company's manufacturing facility in Amityville, New York.

Akorn gets FDA warning letter for Illinois plant, shares drop

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration following an inspection of the company's Decatur, Illinois manufacturing plant last year.

Akorn gets warning letter from the FDA

Akorn Inc said on Wednesday it received a warning letter from the U.S. Food and Drug Administration, after the company's Decatur, Illinois manufacturing facility was inspected by the regulatory authority in April and May, 2018.

Akorn CEO to retire after drugmaker fails to salvage Fresenius merger deal

Akorn Inc <AKRX.O> said late on Friday its Chief Executive Officer would retire following the drugmaker's inability to salvage its takeover deal with Germany's Fresenius SE <FREG.DE>.

Akorn to Delaware justices: Chancery’s MAC opinion is ‘new blueprint for remorseful buyers’

The global pharmaceutical company Fresenius received a rude shock in the summer of 2017 when Akorn, the generic drugmaker Fresenius had agreed to acquire for $4.75 billion, reported its quarterly financial results. The results were terrible – far worse than Fresenius’ gloomiest...

Delaware judge says Fresenius can walk away from $4.8 billion Akorn deal

Germany's Fresenius SE <FREG.DE> won a rare court ruling allowing the healthcare group to walk away from its $4.75 billion takeover of Akorn Inc <AKRX.O>, sparking a more than 50 percent fall in the U.S. generic drugmaker's shares.

Judge rules for Fresenius in bid to end $4.8 bln Akorn deal

A Delaware judge ruled on Monday that German healthcare group Fresenius SE could walk away from its $4.75 billion deal for U.S. drugmaker Akorn Inc and rejected Akorn's claim that the merger agreement had been breached.

Fresenius shares jump on report of win in Akorn ruling

Shares in German healthcare group Fresenius <FREG.DE> surged up 9.3 percent on Monday after a Bloomberg report that the firm won a ruling to pull out of a $4.3 billion deal to buy U.S. generic pharmaceuticals company Akorn <AKRX.O>.

Judge invokes inherent power to police mootness fees in M&A challenge

The class action watchdogs at the Competitive Enterprise Institute lost a battle this week in their challenge to a $322,500 mootness fee for shareholders' lawyers who sued over Akorn Corporation’s M&A deal with Fresenius Kabi AG. U.S. District Judge Thomas Durkin of Chicago...

Fresenius CEO defends canceled Akorn deal

Fresenius SE's <FREG.DE> chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn <AKRX.O>, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius CEO defends cancelled Akorn deal

Fresenius SE's chief executive has defended the company's decision to pull out of a planned $4.8 billion takeover of Akorn, saying it was the only option after uncovering data integrity breaches at the U.S drugmaker.

Fresenius sees Akorn lawsuit dragging on into 2019

German healthcare group Fresenius SE <FREG.DE> said on Thursday its legal battle with Akorn <AKRX.O> over its canceled $4.7 billion takeover could drag on into 2019 as it posted a slight decline in quarterly profit hurt by a strong euro.

Fresenius alleges 'blatant fraud' at U.S. drugmaker Akorn

German healthcare group Fresenius <FREG.DE> alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc <AKRX.O> after Fresenius agreed to acquire the company for $4.75 billion, according to a court filing made public late on Tuesday.

BRIEF-Del. Court says Akorn-Fresenius Trial To Begin July 9

* DELAWARE COURT ORDERS AKORN-FRESENIUS TRIAL TO BEGIN JULY 9, WILL LAST ONE WEEK Further company coverage: (Reporting By Michael Erman)

Fresenius alleges "blatant fraud" at abandoned target Akorn

German healthcare group Fresenius alleged it uncovered "blatant fraud at the very top level" of U.S. generic drugmaker Akorn Inc after Fresenius agreed to acquire the company for $4.75 billion, according to a filing in Delaware's Court of Chancery.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up